1 completed, 1 terminated, 1 withdrawn. 2 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Terminated 1, Withdrawn 1 |
| Phase 2 | 1 | Completed 1 |
Follow Higher Risk Myelodysplastic Syndrome: new trials by email Literature Review of Higher Risk Myelodysplastic Syndrome trials Research Report on Higher Risk Myelodysplastic Syndrome
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| AMG 176 With Azacitidine in Subjects With Myelodysplastic Syndrome /Chronic Myelomonocytic Leukemia AMG 176, Azacitidine - Higher Risk Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia | Phase 1 | Terminated | Amgen | 7 | 2022-11-14 | 2025-07-14 |
| A Study of Bisantrene Combined With Cytarabine or With Decitabine for Adult Subjects With Extramedullary AML and MDS Bisantrene Dihydrochloride (high dose), Bisantrene Dihydrochloride (low dose), Cytarabine Hydrochloride - Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia | Phase 1 | Withdrawn | Racura Oncology Ltd | 2022-07-29 | 2023-10-03 | |
| Nivolumab and Oral Cyclophosphamide for R/R AML and HIgh Risk MDS Nivolumab, Low dose Cyclophosphamide (CTX) Daily, Low dose Cyclophosphamide (CTX) Every 7 Days - Acute Myeloid Leukemia, Higher Risk Myelodysplastic Syndrome | Phase 2 | Completed | Masonic Cancer Center, University of Minnesota | 12 | 2018-08-13 | 2023-05-26 |
Leukemia, Myeloid, Acute (2) · Leukemia, Myelomonocytic, Chronic (2) · Myelodysplastic Syndromes (1)
Hematologic Diseases (3) · Hemic and Lymphatic Diseases (3) · Leukemia (3) · Leukemia, Myeloid (3) · Neoplasms (3) · Neoplasms by Histologic Type (3) · Bone Marrow Diseases (2) · Chronic Disease (2) · Disease Attributes (2) · Myelodysplastic-Myeloproliferative Diseases (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2)
Arabinofuranosylcytosine Triphosphate (1) · Azacitidine (1) · Cyclophosphamide (1) · Cytarabine (1) · Nivolumab (1) · bisantrene (1) · decitabine and cedazuridine drug combination (1) · tapotoclax (1)
Amgen (1) · Masonic Cancer Center, University of Minnesota (1) · Racura Oncology Ltd (1)
United States (2) · Australia (1)
Fiona He, MD (1) · Marinella Messina, PhD (1)